Tuberculosis can have a variety of extrapulmonary manifestations in addition to the classic pulmonary disease. In the August 2005 issue of The Journal of Respiratory Diseases, we reviewed the most common extrapulmonary manifestations of tuberculosis--pleural and lymph node involvement. In this article, we will focus on the presentation of neurologic tuberculosis.
Neurologic tuberculosis occurs in 10% to 15% of patients who have extrapulmonary involvement. It occurs more frequently in children than in adults and is most common in children aged 3 years or younger. The prognosis is generally poor in young children, children of any age who have not received BCG vaccination, and adults who are older than 50 years.
Neurologic involvement is 5 times more frequent in HIV-positive patients than in HIV-negative patients. HIV infection does not generally alter the clinical presentation or response to antituberculosis therapy, although a poorer prognosis can be expected in patients with CD4+ T-lymphocyte counts below 200/µL.1,2 Poor outcomes have also been associated with infection with drug-resistant mycobacterial strains.1
The 3 clinicopathologic categories of neurologic tuberculosis are meningitis, tuberculoma (intracranial and spinal), and arachnoiditis (basal, opticochiasmatic, and spinal).3
Almost 80% of patients with neurologic tuberculosis have meningitis. Tuberculous meningitis continues to be a significant public health concern in developing countries.
CNS tuberculosis is invariably secondary to tuberculosis elsewhere in the body. Meningitis is the result of the rupture of a subependymally located tubercle (Rich focus) that developed during primary hematogenous dissemination into the subarachnoid space.
The pathology includes inflammatory meningeal exudates, ependymitis, vasculitis, and encephalitis. The blockage of the basal cisterns by the exudate in the acute stage and adhesive leptomeningitis in the chronic stage results in the development of communicating hydrocephalus in most patients who have been symptomatic for more than 2 to 3 weeks.
The hydrocephalus is more severein children than in adults. Infrequently, the hydrocephalus is of the obstructive type.3,4
The clinical presentation of tuberculous meningitis has evolved in the past decade and includes an acute meningitic syndrome simulating pyogenic meningitis, progressive dementia, status epilepticus, psychosis, stroke syndrome, and movement disorders. The factors responsible for this changing patterninclude delay in the age at onset of primary infection, BCG immunization,and HIV infection.3,4
The prodromal phase of constitutional features (low-grade fever, anorexia, and lethargy) lasts about 3 weeks. Subsequently, headache and vomiting occur, and the patient has a more toxic appearance. Cranial nerve palsies (especially sixth nerve involvement) and seizures occur in approximately one third of cases.
The loss of vision (clinical and/or impaired visual evoked response) is a major complication of optic pathway involvement and is reported in almost 50% of patients. There is progressive deterioration in sensorium as a result of increasing hydrocephalus and tentorial herniation. The disease is usually fatal within 2 months, if it is untreated.
Encephalopathy is the result of a hypersensitivity reaction to tuberculoproteins. It typically occurs in children and is characterized by diffuse brain edema and white matter disease with minimal evidence of meningitis.
1. Sharma SK, Ahluwalia G. HIV and tuberculosis. Indian J Chest Dis Allied Sci. 2000; 42: 77-81.
2. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med. 1992;326:668-672.
3. Tandon PN, Bhatia R, Bhargava S. Tuberculous meningitis. In: Harrris A, ed. Handbook of Clinical Neurology (revised series). Amsterdam: Elsevier Science; 1988:195-226.
4. Kent SJ, Crowe SM, Yung A, et al. Tuberculous meningitis: a 30 year review. Clin Infect Dis. 1993;17:987-994.
5. Ahuja GK, Mohan KK, Prasad K, Behari M. Diagnostic criteria for tuberculous meningitis and their validation. Tuber Lung Dis. 1994; 75: 149-152.
6. Park SC, Lee BI, Cho SN, et al. Diagnosis of tuberculous meningitis by detection of immunoglobulin G antibodies to purified protein derivative and lipoarabinomannan antigen in cerebrospinal fluid. Tuber Lung Dis. 1993; 74: 317-322.
7. Ashtekar MD, Dhalla AS, Mazarello TB, Samuel AM. A study of Mycobacterium tuberculosis antigen and antibody in cerebrospinal fluid and blood in tuberculous meningitis. Clin Immunol Immunopathol. 1987;45:29-34.
8. Patil SA, Gourie-Devi M, Anand AR, et al. Significance of mycobacterial immune complexes (IgG) in the diagnosis of tuberculous meningitis. Tuber Lung Dis. 1996;77:164-167.
9. Kox LF, Kuijper S, Kolk AH. Early diagnosis of tuberculous meningitis by polymerase chain reaction. Neurology. 1995;45:2228-2232.
10. Berger JR. Tuberculous meningitis. Curr Opin Neurol. 1994;7:191-200.
11. Maher D, Chaulet P, Spinacci S, Harries A. Global Tuberculosis Program, Second Edition. Geneva: World Health Organization; 1997.
12. Humphries M. The management of tuberculous meningitis. Thorax. 1992;47:577-581.
13. Prasad K, Volmink J, Menon GR. Steroids for treating tuberculous meningitis. Cochrane Database Syst Rev. 2000;(3):CD002244.
14. Prasad K, Menon GR. Tuberculous meningitis: the present status and a viewpoint. J Assoc Physicians India. 1997;45: 722- 729.
15. Ranjan P, Kalita J, Misra UK. Serial study of clinical and CT changes in tuberculous meningitis. Neuroradiology. 2003;45:277-282.
16. Teoh R, Humphries MJ, O'Mahony G. Symptomatic intracranial tuberculoma developing during treatment of tuberculosis. Q J Med. 1987;63:449-460.
17. Swaminathan S. Treatment of tuberculosis. Indian J Pediatr. 2000;67(2 suppl):S14-S20.
18. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 1994;149:1359-1374.
19. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 1998;53:536-548.